{"id":"https://genegraph.clinicalgenome.org/r/f09fc288-1304-42fc-8d61-4e2a42c716f7v1.0","type":"EvidenceStrengthAssertion","dc:description":"AP2M1 was first reported in relation to autosomal dominant complex neurodevelopmental disorder in 2019 (Helbig et al., PMID:31104773). The phenotype includes global developmental delay and intellectual disability, often associated with seizures, hypotonia, ataxia, and/or autism. Nine missense variants and one splice site variant have been reported in 14 probands from 9 publications (PMIDs: 36553572, 31104773, 37838930, 33057194, 31785789, 35982159, 28714951, 35982160, 37393044), all of which are included in this curation. The recurrent c.508C>T (p.Arg170Trp) variant has been identified as a de novo variant in five probands including four individuals with developmental and epileptic encephalopathy (DEE) (PMID:31104773, 37393044). The mechanism of pathogenicity is currently unknown. \n\nIn summary, there is definitive evidence supporting the relationship between AP2M1 and autosomal dominant neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. \n\nThis classification was approved by the ClinGen Epilepsy GCEP on the meeting date October 1, 2024 (SOP Version 11).\n\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/f09fc288-1304-42fc-8d61-4e2a42c716f7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/800ffff6-7cf0-4131-aa96-e3bb4f0bde76","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/800ffff6-7cf0-4131-aa96-e3bb4f0bde76_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2024-11-25T21:36:53.650Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/800ffff6-7cf0-4131-aa96-e3bb4f0bde76_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2024-10-01T17:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/800ffff6-7cf0-4131-aa96-e3bb4f0bde76_experimental_evidence_line","type":"EvidenceLine","specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/800ffff6-7cf0-4131-aa96-e3bb4f0bde76_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f60d8223-7d17-4870-9e36-93f2c0d952c9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f60d8223-7d17-4870-9e36-93f2c0d952c9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36553572","allele":{"id":"https://genegraph.clinicalgenome.org/r/51e90590-ef5d-4385-b2ae-3d026e07a134","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.73G>A (p.Gly25Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355419662"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c645ca77-82d5-48dd-bcef-d363abbe7ac2","type":"EvidenceLine","dc:description":"Upgrade to maximum points since this is a recurrent de novo variant with strong functional data and a consistent phenotype in all reported patients.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c645ca77-82d5-48dd-bcef-d363abbe7ac2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"HeLa cells expressing p.Arg170Trp showed reduced levels of internalized AlexaFluor647-labeled transferrin after 10 min compared with cells expressing the WT complex. Both WT and variant co-localize with clathrin, suggesting localization in clathrin-coated pits is not altered. The variant does not affect expression levels, stability, or membrane recruitment of AP-2 complexes. These results suggest the variant impairs clathrin dependent endocytosis, possibly via altered recognition potential of cargo membrane proteins.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c645ca77-82d5-48dd-bcef-d363abbe7ac2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31104773","allele":{"id":"https://genegraph.clinicalgenome.org/r/cea71bb9-8fcd-459e-8e07-ba111ff46354","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.508C>T (p.Arg170Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355424353"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/bdd24e34-c6f4-4818-8d7e-bb121b2fe413","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bdd24e34-c6f4-4818-8d7e-bb121b2fe413_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31785789","allele":{"id":"https://genegraph.clinicalgenome.org/r/21755b2f-b095-4ea2-bc56-7c5156aef60d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.98G>A (p.Arg33Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355420055"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/dc95ce40-54bf-4acb-87dd-310f2e935699","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dc95ce40-54bf-4acb-87dd-310f2e935699_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28714951","allele":{"id":"https://genegraph.clinicalgenome.org/r/5d43234f-b72c-418c-b6ff-59e67d71b4da","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.828-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355427621"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/86531f48-f10d-41d8-a7be-6a33af93aaab","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86531f48-f10d-41d8-a7be-6a33af93aaab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37838930","allele":{"id":"https://genegraph.clinicalgenome.org/r/e6db2856-8ed4-49c0-944f-a8fce75a9218","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.916G>A (p.Val306Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355428248"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2feaa836-2f3d-41c0-9a4d-65df75dbdcfd","type":"EvidenceLine","dc:description":"Upgrade to maximum points since this is a recurrent de novo variant with strong functional data and a consistent phenotype in all reported patients.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2feaa836-2f3d-41c0-9a4d-65df75dbdcfd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"HeLa cells expressing p.Arg170Trp showed reduced levels of internalized AlexaFluor647-labeled transferrin after 10 min compared with cells expressing the WT complex. Both WT and variant co-localize with clathrin, suggesting localization in clathrin-coated pits is not altered. The variant does not affect expression levels, stability, or membrane recruitment of AP-2 complexes. These results suggest the variant impairs clathrin dependent endocytosis, possibly via altered recognition potential of cargo membrane proteins.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2feaa836-2f3d-41c0-9a4d-65df75dbdcfd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31104773","allele":{"id":"https://genegraph.clinicalgenome.org/r/cea71bb9-8fcd-459e-8e07-ba111ff46354"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a04558ac-9b09-4549-9757-a72c6f699664","type":"EvidenceLine","dc:description":"Upgrade to maximum points since this is a recurrent de novo variant with strong functional data and a consistent phenotype in all reported patients.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a04558ac-9b09-4549-9757-a72c6f699664_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"HeLa cells expressing p.Arg170Trp showed reduced levels of internalized AlexaFluor647-labeled transferrin after 10 min compared with cells expressing the WT complex. Both WT and variant co-localize with clathrin, suggesting localization in clathrin-coated pits is not altered. The variant does not affect expression levels, stability, or membrane recruitment of AP-2 complexes. These results suggest the variant impairs clathrin dependent endocytosis, possibly via altered recognition potential of cargo membrane proteins.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a04558ac-9b09-4549-9757-a72c6f699664_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37393044","allele":{"id":"https://genegraph.clinicalgenome.org/r/cea71bb9-8fcd-459e-8e07-ba111ff46354"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5da5da2c-eaca-4a54-bd88-75681354437e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5da5da2c-eaca-4a54-bd88-75681354437e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33057194","allele":{"id":"https://genegraph.clinicalgenome.org/r/ceaf81d7-e824-4ae1-8fe1-a25a054e6054","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.157A>G (p.Thr53Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355420313"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/09028ef1-1d3a-4c06-a4de-930227471ef2","type":"EvidenceLine","dc:description":"Upgrade to maximum points since this is a recurrent de novo variant with strong functional data and a consistent phenotype in all reported patients.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09028ef1-1d3a-4c06-a4de-930227471ef2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"HeLa cells expressing p.Arg170Trp showed reduced levels of internalized AlexaFluor647-labeled transferrin after 10 min compared with cells expressing the WT complex. Both WT and variant co-localize with clathrin, suggesting localization in clathrin-coated pits is not altered. The variant does not affect expression levels, stability, or membrane recruitment of AP-2 complexes. These results suggest the variant impairs clathrin dependent endocytosis, possibly via altered recognition potential of cargo membrane proteins","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/09028ef1-1d3a-4c06-a4de-930227471ef2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31104773","allele":{"id":"https://genegraph.clinicalgenome.org/r/cea71bb9-8fcd-459e-8e07-ba111ff46354"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/37e47057-a4cf-4cf7-b8f7-f38b61972f71","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/37e47057-a4cf-4cf7-b8f7-f38b61972f71_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35982160","allele":{"id":"https://genegraph.clinicalgenome.org/r/cd3d4f60-83fc-43a6-9041-574df7d94499","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.473A>G (p.Gln158Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355424113"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cb5aae65-ddd4-474f-b5f7-4db5de64abe5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb5aae65-ddd4-474f-b5f7-4db5de64abe5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31785789","allele":{"id":"https://genegraph.clinicalgenome.org/r/546ae53a-9db8-4920-8080-d5679ebfb84b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.755T>C (p.Val252Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355427111"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/be5034db-cf36-45d8-a6f9-987dd3f33776","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be5034db-cf36-45d8-a6f9-987dd3f33776_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35982160","allele":{"id":"https://genegraph.clinicalgenome.org/r/d3c951d8-3117-4dd6-8377-087aaf47fb86","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004068.4(AP2M1):c.490G>A (p.Glu164Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA355424232"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ba7b6490-fac3-4aed-a401-545a741b8306","type":"EvidenceLine","dc:description":"Upgrade to maximum points since this is a recurrent de novo variant with strong functional data and a consistent phenotype in all reported patients.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba7b6490-fac3-4aed-a401-545a741b8306_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"HeLa cells expressing p.Arg170Trp showed reduced levels of internalized AlexaFluor647-labeled transferrin after 10 min compared with cells expressing the WT complex. Both WT and variant co-localize with clathrin, suggesting localization in clathrin-coated pits is not altered. The variant does not affect expression levels, stability, or membrane recruitment of AP-2 complexes. These results suggest the variant impairs clathrin dependent endocytosis, possibly via altered recognition potential of cargo membrane proteins.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ba7b6490-fac3-4aed-a401-545a741b8306_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31104773","allele":{"id":"https://genegraph.clinicalgenome.org/r/cea71bb9-8fcd-459e-8e07-ba111ff46354"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":11.5}],"evidenceStrength":"Definitive","sequence":9409,"specifiedBy":"GeneValidityCriteria11","strengthScore":11.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/tGTi40Ebkg0","type":"GeneValidityProposition","disease":"obo:MONDO_0100038","gene":"hgnc:564","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_800ffff6-7cf0-4131-aa96-e3bb4f0bde76-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}